Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NuGen Medical Devices Inc. (NGMDF)
Toronto, ON, CA
NuGen Medical Devices Inc. is a specialized firm dedicated to pioneering and marketing advanced drug delivery solutions. The company's core offering comprises innovative needle-free injection devices and systems, designed for subcutaneous medication delivery across a broad spectrum of medical conditions and therapeutic applications. These include treatments for anaphylaxis, diabetes management, severe migraine, erectile dysfunction, chronic anemia, neutropenia, and autoimmune rheumatoid arthritis, further extending to growth and fertility hormone therapies, psoriasis treatment, and various vaccine types including DNA, conventional, and pediatric formulations. Previously, the organization operated under the name BuzBuz Capital Corp., and its operational base is situated in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +14.96% | -46.89% | -46.13% | -41.60% | +14,500.00% | -91.46% | -91.15% | -91.15% | -91.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%-74.5% Q1'26: -78.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-41.0% Q1'26: -205.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-2,778.8% Q1'26: -5,507.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-1,636.2% Q1'26: -4,870.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-933.6% Q1'26: -635.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+5.8% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-4.92× Q1'26: -4.32× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicky Canton | Executive Vice President & Chief Operating Officer | 140.1K | male |
| Karen Dunlap | Interim Chief Customer Officer & Independent Director | 104.8K | female |
| Ajay Mishra | CFO & Corporate Secretary | — | male |
| Elisha Dillon | Head of Global Sales & Strategic Partnerships | — | female |
| Lin Liang | Chief Executive Officer & Executive Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NGMDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
